News	Drug Formulary	Safety Net	Resources
	Drug Formulary Categories and Charges Search HA Drug Formulary Self-financed Drugs Available for Purchase by Patients at HA Pharmacy How we evaluate new drugs Governance Drug Management Committee Drug Advisory Committee Drug Formulary Committee Drug & Therapeutics Committee Drug Selection Committee Expert Panel Medication Safety Committee	Samaritan Fund Community Care Fund	Drug Education HA Drug Formulary Management Manual Frequently Asked Questions Useful Links

药物建议委员会审议结果

DAC Meeting Outcome - Apr 2024

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection¹
1	Adalimumab	Amgevita	Gastro-intestinal system	Approved
2	Atezolizumab	Tecentriq	Malignant disease and immunosuppression	Approved
3	Bempedoic acid	Nilemdo	Cardiovascular system	Rejected	Alternative(s) available in HADF with comparable benefits
4	Dostarlimab	Jemperli	Malignant disease and immunosuppression	Approved
5	Fluticasone/Umeclidinium/Vilanterol	Trelegy Ellipta	Respiratory system	Pending	Pending further information
6	Glycerol phenylbutyrate	Ravicti	Nutrition and blood	Rejected	The justification of the treatment’s cost in relation to its benefits is insufficient
7	Golimumab	Simponi	Musculoskeletal and joint disease	Pending	Pending further information
8	Insulin glargine	Toujeo	Endocrine system	Approved
9	Lemborexant	Dayvigo	Central nervous system	Rejected	Insufficient evidence of long-term safety
10	Lenalidomide	Revlimid	Malignant disease and immunosuppression	Approved
11	Lutetium 177 vipivotide tetraxetan	Pluvicto	Radiopharmaceuticals	Pending	Pending further information
12	Nivolumab	Opdivo	Malignant disease and immunosuppression	Rejected	Insufficient evidence of long-term clinical outcome benefits / The justification of the treatment’s cost in relation to its benefits is insufficient
13	Nivolumab / Ipilimumab	Opdivo/ Yervoy	Malignant disease and immunosuppression	Approved
14	Pembrolizumab	Keytruda	Malignant disease and immunosuppression	Approved
15	Pembrolizumab / Axitinib	Keytruda/ Inlyta	Malignant disease and immunosuppression	Rejected	The justification of the treatment’s cost in relation to its benefits is insufficient
16	Safinamide	Equfina	Central nervous system	Rejected	Insufficient comparative studies versus existing treatment
17	Trastuzumab Deruxtecan	Enhertu	Malignant disease and immunosuppression	Approved
18	Upadacitinib	Rinvoq	Gastro-intestinal system	Rejected	The justification of the treatment’s cost in relation to its benefits is insufficient
19	Vedolizumab	Entyvio	Gastro-intestinal system	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits